EXOZ eXoZymes
eXoZymes earnings company data as of 4:47 AM ET 10/22
History
2 periods, newest first. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 12 Nov | EPS | — | — | — |
| Rev | — | — | — | ||
| FY2026 Q2 | 13 Aug | EPS | — | -0.61 | — |
| Rev | — | — | — |
Insider trades
Open-market buys and sales by EXOZ's executives, directors and 10% owners in the last 12 months, from their Form 4s
- $6,405 bought by 1 insider
- $15K sold by 1 insider outside a trading plan
- None no planned (10b5-1) sales
-
Michael Heltzen CEOBuy$6,405 855 shares at $7.49 +6.3% to stakeTraded Aug 25–26 Filed Sep 2
-
Tyler Paz Korman Chief Scientific OfficerSale$15K 1,500 shares at $10.28 0.2% of stakeTraded Apr 8–9 Filed Apr 10
Also filed in the last 12 months, not counted as buying or selling: 6 stock grants and 2 option exercises.
SEC filings
Recent issuer filings from EDGAR, 23 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| 8-K | 8.01,9.01 | Filing Doc | |
| DEF 14A | Filing Doc | ||
| DEFA14A | Filing Doc | ||
| 8-K | 8.01,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 1.01,9.01 | Filing Doc | |
| 424B5 | Filing Doc | ||
| 8-K | 7.01,9.01 | Filing Doc | |
| 8-K | 1.01,7.01,9.01 | Filing Doc | |
| 424B5 | Filing Doc | ||
| 8-K | 1.01,7.01,9.01 | Filing Doc | |
| 424B5 | Filing Doc | ||
| 424B5 | Filing Doc | ||
| 10-Q | Filing Doc | ||
| 8-K | 8.01,9.01 | Filing Doc | |
| 8-K | 8.01,9.01 | Filing Doc | |
| 424B5 | Filing Doc | ||
| 8-K | 8.01,9.01 | Filing Doc | |
| 10-K | Filing Doc | ||
| 8-K | 8.01,9.01 | Filing Doc | |
| 424B2 | Filing Doc | ||
| 8-K | 8.01,9.01 | Filing Doc | |
| 8-K | 8.01,9.01 | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.